Advertisement
This marks the first time Bavarian Nordic enters a contract with an EUcountry for the delivery of IMVAMUNE(R), and it demonstrates that thereexists a real demand inside of EU for new and safer smallpox vaccines forpreparedness stockpiles.
Advertisement
This contract does not affect the company's expectations for the 2009full year results.
Anders Hedegaard, President & CEO of Bavarian Nordic said: "Entering thefirst contract with an EU country on IMVAMUNE(R) demonstrates the need fornew and safer smallpox vaccines. We have a continued ongoing positivedialogue with governments in and outside the EU, and we expect that this willlead to several smaller contracts. When we expectedly receive the approvalfrom the US authorities to initiate the delivery of IMVAMUNE(R) under theRFP-3 contract for 20 million doses, this will be an important message toother governments currently considering to stockpile IMVAMUNE(R)."
Forward-looking statements
This announcement includes "forward-looking statements" that involverisks, uncertainties and other factors, many of which are outside of ourcontrol that could cause actual results to differ materially from the resultsdiscussed in the forward-looking statements. Forward-looking statementsinclude statements concerning our plans, objectives, goals, future events,performance and/or other information that is not historical information. Weundertake no obligation to publicly update or revise forward-lookingstatements to reflect subsequent events or circumstances after the date made,except as required by law.
About Bavarian Nordic
Bavarian Nordic A/S is a leading industrial biotechnology companydeveloping and producing novel vaccines for the treatment and prevention oflife-threatening diseases with a large unmet medical need. The company'spipeline is focused in the three areas; biodefence, cancer and infectiousdiseases, and includes seven development programmes. Two programmes are readyfor Phase III: IMVAMUNE(R), a third-generation smallpox vaccine is beingdeveloped under a contract with the US government, and PROSTVAC(TM), atherapeutic vaccine for advanced prostate cancer is being developed under acollaboration agreement with the National Cancer Institute.
Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.
For more information please visit http://www.bavarian-nordic.com
SOURCE Bavarian Nordic A/S
